What's so special about model organisms? Studies in History and Philosophy of Science A, 42, 313e323, 2011. ,
Models and the mosaic of scientific knowledge. The case of immunology, Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, vol.45, issue.49e56, 2014. ,
DOI : 10.1016/j.shpsc.2013.11.003
The ???Big Picture???: The Problem of Extrapolation in Basic Research, 941e964, 2016. ,
DOI : 10.1093/bjps/axv018
Antibody C Region Influences TGN1412-like Functional Activity In Vitro, The Journal of Immunology, vol.189, issue.12, pp.5831-5840, 1950. ,
DOI : 10.4049/jimmunol.1201795
Risk in drug trials, The Lancet, vol.368, issue.9554, pp.2205-0140, 2006. ,
DOI : 10.1016/S0140-6736(06)69882-6
Cell contact-dependent priming and Fc interaction with CD32þ immune cells contribute to the TGN1412-triggered cytokine response, Journal of Immunology, vol.192, issue.5, 1950. ,
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis, The Journal of Experimental Medicine, vol.160, issue.3, pp.445-455, 2005. ,
DOI : 10.1073/pnas.92.13.5850
Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases, Annals of the Rheumatic Diseases, vol.64, issue.suppl_4, 2005. ,
DOI : 10.1136/ard.2005.042564
CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells, Autoimmunity Reviews, vol.5, issue.1, pp.40-45, 2006. ,
DOI : 10.1016/j.autrev.2005.06.001
Mechanisms and the Evidence Hierarchy, Topoi, vol.16, issue.3, pp.339-360, 2014. ,
DOI : 10.1007/s11245-013-9220-9
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.400.32
Explaining the Brain: Mechanisms and the mosaic unity of neuroscience, 2007. ,
DOI : 10.1093/acprof:oso/9780199299317.001.0001
Agency criticises drug trial, BMJ, vol.332, issue.7553, 1290. ,
DOI : 10.1136/bmj.332.7553.1290-a
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473072
Evaluating Animal Models: Some Taxonomic Worries, Journal of Medicine and Philosophy, vol.38, 2013. ,
DOI : 10.1093/jmp/jht004
URL : http://jmp.oxfordjournals.org/cgi/content/short/38/2/91
A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies, Journal of Immunotoxicology, vol.2, issue.1, pp.34-42, 2012. ,
DOI : 10.1080/15476910801897433
The Northwick Park tragedyeprotecting healthy volunteers in future first-in-man trials, Journal of Clinical Pharmacy and Therapeutics, vol.32, 2007. ,
Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4þ effector memory T-cells, British Journal of Pharmacology, vol.161, issue.3, 2010. ,
Risk in drug trials, The Lancet, vol.368, issue.9554, pp.140-673669884, 2006. ,
DOI : 10.1016/S0140-6736(06)69884-X
From replica to instruments: animal models in biomedical research, History and Philosophy of the Life Sciences, vol.51, issue.9, 2014. ,
DOI : 10.1007/s40656-014-0007-0
Further lessons from the TGN1412 tragedy, BMJ, vol.333, issue.7562, pp.270-271, 2006. ,
DOI : 10.1136/bmj.38929.647662.80
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526936
Regulatory Affairs Introduction, Toxicologic Pathology, vol.37, issue.3, pp.361-362, 2009. ,
DOI : 10.1056/NEJMoa063842
Could the GI tract be a better portal for antibody therapy? Gut, pp.1681-1682, 2006. ,
TGN1412: scrutinizing preclinical trials of antibody-based medicines, Nature, vol.440, issue.7091, 2006. ,
DOI : 10.1038/441282a
Minimising risk in first-in-man trials, The Lancet, vol.369, issue.9572, pp.140-673660686, 2007. ,
DOI : 10.1016/S0140-6736(07)60686-2
Models and analogies in science, new edition, 1970. ,
The TeGenero incident and the duff report conclusions: A series of unfortunate events or an avoidable event? Toxicologic Pathology, 2009. ,
The philosophy of evidence-based medicine, Bmj Books), 2011. ,
Mutant mice: Experimental organisms as materialised models in biomedicine, Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, vol.44, issue.3, pp.385-391, 2013. ,
DOI : 10.1016/j.shpsc.2013.03.001
Establishing risk of human experimentation with drugs: lessons from TGN1412, The Lancet, vol.368, issue.9544, pp.140-673669562, 2006. ,
DOI : 10.1016/S0140-6736(06)69562-7
Two Models of Models in Biomedical Research, The Philosophical Quarterly, vol.45, issue.179, pp.45-141, 1995. ,
DOI : 10.2307/2220412
Standard-based reasoning in preclinical studies: Challenging the received view on extrapolation . forthcoming, Uncertainty in pharmacology, 2016. ,
Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics, Drug Metabolism & Disposition, vol.26, 1998. ,
Superagonistic anti-CD28 antibody TGN1412 as a potential immunotherapeutic for the Treatment of B Cell chronic lymphocytic leukemia, ASH Annual Meeting Abstracts, p.2519, 2004. ,
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist, 626e 638, 2003. ,
DOI : 10.1002/eji.200323570
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment, Critical Reviews in Oncology/Hematology, vol.62, issue.1, 2007. ,
DOI : 10.1016/j.critrevonc.2006.11.010
Humanised models of cancer in molecular medicine: The experimental control of disanalogy. Medicines and Healthcare Products Regulatory Agency Investigations into adverse incidents during clinical trials of TGN1412, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00803910
Fas ligand-mediated cytotoxic function induced by mitogenic CD28 stimulation of human memory CD4þ T cells, Journal of Leukocyte Biology, vol.91, issue.5, pp.759-771 ,
The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development, Toxicologic Pathology, vol.47, issue.3, pp.363-371, 2009. ,
DOI : 10.1177/0192623309332997
Modeling mouse, human, and discipline: Epistemic scaffolds in animal behavior genetics, Social Studies of Science, vol.114, issue.1, pp.3-29, 2013. ,
DOI : 10.1177/030631289019003001
Risk in drug trials, The Lancet, vol.368, issue.9554, pp.140-673669883, 2006. ,
DOI : 10.1016/S0140-6736(06)69883-8
Primate testing of TGN1412: right target, wrong cell, British Journal of Pharmacology, vol.355, issue.3, 2010. ,
DOI : 10.1111/j.1476-5381.2010.00925.x
Triggering of T cell proliferation through CD28 induces GATA-3 and promotes T helper type 2 differentiation in vitro and in vivo, 12<3914::AID- IMMU3914>3.0.CO, pp.3914-39241521, 1999. ,
DOI : 10.1002/(SICI)1521-4141(199912)29:12<3914::AID-IMMU3914>3.3.CO;2-R
Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412, Blood, vol.118, issue.26, pp.6772-6782, 2011. ,
DOI : 10.1182/blood-2010-12-319780
Interpreting Causality in the Health Sciences, International Studies in the Philosophy of Science, vol.14, issue.2, pp.157-170, 2007. ,
DOI : 10.1007/s10849-005-9010-x
EnviroGenomarkers: The Interplay Between Mechanisms and Difference Making in Establishing Causal Claims, Medicine Studies, vol.6, issue.6, pp.249-262, 2012. ,
DOI : 10.1007/s12376-012-0079-7
Genes, Behavior, and Developmental Emergentism: One Process, Indivisible?, Philosophy of Science, vol.65, issue.2, pp.209-252, 1998. ,
DOI : 10.1086/392635
Behavior at the Organismal and Molecular Levels: The Case of C. elegans, Philosophy of Science, vol.67, p.288, 2000. ,
DOI : 10.1086/392825
Behaving: What's genetic and What's not, and why should we care, 2016. ,
DOI : 10.1093/acprof:oso/9780195171402.001.0001
TGN1412ea regulator's perspective, Nature Biotechnologies, vol.24, issue.493e496, pp.506-493, 2006. ,
How specific are therapeutic monoclonal antibodies? Lancet, pp.140-6736, 2006. ,
DOI : 10.1016/s0140-6736(06)68396-7
Mechanisms of costimulation, Immunological Reviews, vol.26, issue.1, pp.5-11, 2009. ,
DOI : 10.1111/j.1600-065X.2009.00784.x
After the London tragedy, is it still possible to consider Phase I is safe?, British Journal of Clinical Pharmacology, vol.62, issue.4, 2006. ,
DOI : 10.1016/j.clpt.2005.12.256
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885163
After TGN1412: Recent developments in cytokine release assays, Journal of Immunotoxicology, vol.94, issue.1, pp.75-82, 2013. ,
DOI : 10.3109/1547691X.2011.613419
"Cytokine Storm" in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics, The Journal of Immunology, vol.179, issue.5, pp.179-3325, 1950. ,
DOI : 10.4049/jimmunol.179.5.3325
Across the Boundaries: Extrapolation in biology and social science, 2008. ,
DOI : 10.1093/acprof:oso/9780195331448.001.0001
Essay: Monoclonal antibodiesddesigner medical missiles. The Lancet, 368, S48eS49, pp.140-673669926, 2006. ,
DOI : 10.1016/s0140-6736(06)69926-1
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412, New England Journal of Medicine, vol.355, issue.10, pp.1018-1028, 2006. ,
DOI : 10.1056/NEJMoa063842
CD28-mediated induction of proliferation in resting T cellsin vitro andin vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28, European Journal of Immunology, vol.79, issue.1, pp.239-247, 1997. ,
DOI : 10.1002/eji.1830270136
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?, British Journal of Clinical Pharmacology, vol.100, issue.Suppl. 2, pp.164-172, 2013. ,
DOI : 10.1111/bcp.12096
Monoclonal antibody testing, Journal of Medical Primatology, vol.441, issue.6, 2006. ,
DOI : 10.1038/437030a
Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies, PLoS ONE, vol.193, issue.3, 2008. ,
DOI : 10.1371/journal.pone.0001708.s005
Philosophy of experimental biology, 2005. ,
DOI : 10.1017/CBO9780511498596
Allergy test might have avoided drug-trial disaster, Nature, vol.440, issue.7090, 2006. ,
DOI : 10.1038/441150c
ICOS-LICOS interaction is critically involved in TGN1412-mediated T-cell activation, Blood, vol.119, issue.26, 2012. ,
DOI : 10.1182/blood-2011-12-401083
The validity of animal models of depression, Psychopharmacology, vol.8, issue.Suppl, pp.1-16, 1984. ,
DOI : 10.1007/BF00427414
Biologics in the Pipeline: Large Molecules With High Hopes or Bigger Risks?, The Journal of Clinical Pharmacology, vol.11, issue.5, 2007. ,
DOI : 10.1177/0091270006297230